通过抑制USP25,通过恢复线粒细胞衰变来改善帕金森病
Yanqi Xu1,2, Keshuo Jin1,2, Jiaqing Chen1,2
1School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou 325035, China.
概括
双化酶USP25通过破坏线粒细胞吸收来使帕金森病 (PD) 恶化. 抑制USP25显示出新的帕金森病治疗方法的前景.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 帕金森病 (PD) 是一种进展性神经退行性疾病,具有重大的全球健康影响.
- USP25基因是已知的PD易感基因,但其在疾病发病过程中的具体作用尚不清楚.
研究的目的:
- 在帕金森病中研究duebiquitinating酶USP25在帕金森病中的作用.
- 为了确定USP25是否可以成为PD的治疗点.
主要方法:
- 使用了PD的小鼠模型.
- 检查了USP25和自细胞受体optineurin之间的相互作用.
- 评估了USP25对线粒细胞衰减和多巴胺能神经元损失的影响.
- 研究了基因切除和药理抑制USP25的效应.
主要成果:
- 发现USP25在PD模型中加剧了多巴胺基神经元损失和运动缺陷.
- USP25通过干扰光氨酸介导链接到K63特异的多比基链来破坏线粒细胞衰变,从而导致受损的线粒体积累.
- 在PD模型小鼠中,USP25的遗传或药理抑制恢复了线粒细胞衰变和减弱的神经退行.
结论:
- USP25在帕金森病的进展中起着至关重要的作用.
- USP25被确定为开发PD新型治疗策略的潜在药理学目标.
更多相关视频
09:29Time-Lapse Video Microscopy for Assessment of EYFP-Parkin Aggregation as a Marker for Cellular Mitophagy
Published on: May 4, 2016
7.5K
06:57Author Spotlight: Fluorescence-Based Quantification of Mitochondrial Membrane Potential and Superoxide Levels Using Live Imaging in HeLa Cells
Published on: May 12, 2023
9.1K
相关概念视频
Parkinson's Disease: Treatment
970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Translocation of Proteins into the Mitochondria
12.1K
Mitochondrial precursors are translocated to the internal subcompartments via independent mechanisms involving distinct protein machineries called translocases.
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
Sorting of outer membrane proteins:
Mitochondrial outer membrane proteins are of two types: the transmembrane, beta-barrel porins, and the membrane-anchored, alpha-helical proteins. Beta-barrel porin precursors are translocated by the TOM complex and inserted into the outer mitochondrial membrane by the SAM complex. In contrast,...
12.1K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
